Last reviewed · How we verify
lidocaine + epinephrine 1:100,000 — Competitive Intelligence Brief
marketed
Local anesthetic with vasoconstrictor
Voltage-gated sodium channels (lidocaine); alpha-1 and beta-1 adrenergic receptors (epinephrine)
Anesthesia
Small molecule
Live · refreshed every 30 min
Target snapshot
lidocaine + epinephrine 1:100,000 (lidocaine + epinephrine 1:100,000) — Weill Medical College of Cornell University. Lidocaine blocks sodium channels to provide local anesthesia, while epinephrine causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| lidocaine + epinephrine 1:100,000 TARGET | lidocaine + epinephrine 1:100,000 | Weill Medical College of Cornell University | marketed | Local anesthetic with vasoconstrictor | Voltage-gated sodium channels (lidocaine); alpha-1 and beta-1 adrenergic receptors (epinephrine) | |
| tetracaine HCl and oxymetazoline HCL | tetracaine HCl and oxymetazoline HCL | Louisiana State University Health Sciences Center in New Orleans | marketed | Local anesthetic with vasoconstrictor combination | Voltage-gated sodium channels (tetracaine); alpha-2 adrenergic receptors (oxymetazoline) | |
| Ropivicaine with Epinephrine | Ropivicaine with Epinephrine | Health Sciences North Research Institute | marketed | Local anesthetic with vasoconstrictor | Voltage-gated sodium channels | |
| Xylocaine with Epinephrine | Xylocaine with Epinephrine | Vrije Universiteit Brussel | marketed | Local anesthetic with vasoconstrictor | Voltage-gated sodium channels; alpha-1 adrenergic receptors | |
| Lidocaine 1%/Epi 1:200000 | Lidocaine 1%/Epi 1:200000 | Wahba bakhet | marketed | Local anesthetic with vasoconstrictor | Voltage-gated sodium channels | |
| Tumescent Solution with dilute epinephrine | Tumescent Solution with dilute epinephrine | University of Wisconsin, Madison | marketed | Local anesthetic with vasoconstrictor | ||
| Levobupivacaine with epinephrine | Levobupivacaine with epinephrine | Pontificia Universidad Catolica de Chile | marketed | Local anesthetic with vasoconstrictor | Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Local anesthetic with vasoconstrictor class)
- Ankara Yildirim Beyazıt University · 1 drug in this class
- Health Sciences North Research Institute · 1 drug in this class
- Ohio State University · 1 drug in this class
- Pontificia Universidad Catolica de Chile · 1 drug in this class
- University Hospital, Antwerp · 1 drug in this class
- University of Wisconsin, Madison · 1 drug in this class
- Vrije Universiteit Brussel · 1 drug in this class
- Wahba bakhet · 1 drug in this class
- Weill Medical College of Cornell University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- lidocaine + epinephrine 1:100,000 CI watch — RSS
- lidocaine + epinephrine 1:100,000 CI watch — Atom
- lidocaine + epinephrine 1:100,000 CI watch — JSON
- lidocaine + epinephrine 1:100,000 alone — RSS
- Whole Local anesthetic with vasoconstrictor class — RSS
Cite this brief
Drug Landscape (2026). lidocaine + epinephrine 1:100,000 — Competitive Intelligence Brief. https://druglandscape.com/ci/lidocaine-epinephrine-1-100-000. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab